MCK241101P497500
- 4.50
- +2.10+87.50%
McKesson Newsroom
Barclays Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $616
BofA Securities Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $635
Analysts Conflicted on These Healthcare Names: Medpace Holdings (MEDP), McKesson (MCK) and Glaukos (GKOS)
BofA Securities Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $635
Morgan Stanley Maintains McKesson(MCK.US) With Buy Rating, Maintains Target Price $612
Morgan Stanley Keeps Their Buy Rating on McKesson (MCK)
TD Cowen Adjusts McKesson Price Target to $642 From $652
UBS Maintains McKesson(MCK.US) With Buy Rating, Cuts Target Price to $590
McKesson Is Maintained at Outperform by Leerink Partners
McKesson Analyst Ratings
Argus Research Maintains McKesson(MCK.US) With Buy Rating, Announces Target Price $570
Argus Adjusts Price Target on McKesson to $570 From $640
Deutsche Bank Maintains McKesson(MCK.US) With Buy Rating, Raises Target Price to $579
Deutsche Bank Maintains Buy on McKesson, Lowers Price Target to $579
Buy Rating Affirmed: McKesson's Long-term Growth Strategy Balances Short-term Earnings Concerns
McKesson Price Target Cut to $531.00/Share From $603.00 by Baird
Baird Downgrades McKesson(MCK.US) to Hold Rating, Cuts Target Price to $531
McKesson: Operational and Strategic Challenges Prompt Hold Rating
McKesson Analyst Ratings
Wells Fargo Maintains Equal-Weight on McKesson, Lowers Price Target to $535